Prognosis

Pandemic Hobbles Drugmakers in Recruiting for New Studies

Novartis pauses new enrollment in U.K. heart drug trial
Regulators ask researchers to use phone, video with patients

Watch: Vas Narasimhan, chief executive officer at Novartis AG, discusses why the company is keeping 2020 forecasts intact, the impact of coronavirus and his business outlook. (Source: Bloomberg)

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By James Paton

April 28, 2020 at 5:17 AM UTC

Updated on

April 28, 2020 at 5:13 PM UTC

This article is for subscribers only.

Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.

A study evaluating a Novartis AG cholesterol drug stopped enlisting patients due to Covid-19, the latest example of how the pandemic is hampering research across the industry.